SXR rs3842689: A prognostic factor for steroid sensitivity or resistance in pediatric idiopathic nephrotic syndrome

Pharmacogenomics

Volumn 17, Issue 11, 2016, Pages 1227-1233

  Turolo, Stefano ^a,b   Edefonti, Alberto ^a,b   Lepore, Marta ^a,b   Ghio, Luciana ^a,b   Cuzzoni, Eva ^c   Decorti, Giuliana ^c   Pasini, Andrea ^d   Materassi, Marco ^e   Malaventura, Cristina ^f   Pugliese, Fabrizio ^g   Montini, Giovanni ^a,h  

^a U Pediat Nephrology Dialysis T   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g Agenzia Sanitaria e Sociale Regionale Regione Emilia Romagna   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

idiopathic nephrotic syndrome; steroid resistant; steroids; SXR

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE; OXIDOREDUCTASE; SRXN1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE; GENETIC POLYMORPHISM; HUMAN; INDEL MUTATION; INFANT; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; ODDS RATIO; PEDIATRICS; PREDICTION; PROGNOSIS; RISK FACTOR; SXR GENE; DRUG RESISTANCE; GENETICS; PREDICTIVE VALUE; PRESCHOOL CHILD;

ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; HUMANS; MALE; NEPHROTIC SYNDROME; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84979578250     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0029     Document Type: Article

References (24)

1. Arneil GC. 164 children with nephrosis. Lancet 2, 1103-1110 (1961).
2. Eddy AA, Symons JM. Nephrotic sindrome in childhood. Lancet 362, 629-639 (2003).
3. Gipson DS, Massengil SF, Yao L et al. Management of childhood onset nephritic syndrome. Pediatrics 124, 747-757 (2009).
4. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the shapering of an old spear. Lancet 365, 801-803 (2005).
5. Di Blasio AM, van Rossum EF, Maestrini S et al. The relation between two polymorphism in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. 59, 68-74 (2003).
6. Jones TS, Kaste SC, Liu W et al. CRHR1 polymorphism predict bone density in survivors of acute lymphoblastic leucemia J. Clin. Oncol. 26, 3031-3037 (2008).
7. Kamdem LK, Hamilton L, Cheng C et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphobloastic leukaemia. Pharmacogenet. Genomics 18, 507-514 (2008).
8. Farrell RJ, Monconi MJ, Keates AC, Kelly CP. P-glycoprotein-170 inhibitor significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment. Pharm. Ther. 16, 1021-1031 (2002).
9. Yee-Hsuan C, Lin-Yu W, Tzu-Hui W. Genetic polymorphism influence the steroid treatment of children with idiopathic nephritic syndrome; Pediatr. Nephrol. 25, 1511-1517 (2012).
10. Wasilewska A, Zalewski G, Chyczewski L. MDR-1 gene polymorphism and clinical course of steroid-responsive nephritic syndrome in children. Pediatr. Nephrol. 22(1), 44-51 (2007).
11. Jafar T, Prasad N, Agarwal V. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol. Dial. Transplant. 26(12), 3968-3974 (2011).
12. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47, 566-578 (2007).
13. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab. 6, 369-383 (2005).
14. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression Drug Metab. Dispos. 36(1), 169-181 (2007).
15. Cuzzoni E, De Iudicibus S, Bartoli F, Ventura A, Decorti G. NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. Br. J. Clin. Pharmacol. 73(4), 651-6555 (2012).
16. Zalewski G, Wasilewska A, Zoch-Zwierz W, Chyczewski L. Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatr. Nephrol. 23(7), 1073-1078 (2008).
17. Niu N, Manickam V, Kalari KR et al. Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomics. J. Clin. Endocrinol. Metab. 94(8), 3072-3084 (2009).
18. Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 331(4), 815-828 (2003).
19. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol. Cell. Biol. 23(11), 3763-3773 (2003).
20. Kurihara I, Shibata H, Suzuki T et al. Expression and regulation of nuclear receptor coactivators in glucocorticoid action. Mol. Cell. Endocrinol. 189(1-2), 181-189 (2002).
21. Arneil GC. The nephrotic syndrome. Pediatr. Clin. North Am. 18, 547-559 (1971).
22. Ferraresso M, Belingheri M, Turolo S et al. Long-term effect of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients. Pharmacogenomics 14(13), 1605-1613 (2013).
23. Zhang J, Kuehl P, Green ED et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11, 555-572 (2001).
24. Ferraresso M, Turolo S, Belinghieri M et al. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatr. Transplant. 16(6), 658-663 (2012).